Brief: Therapeutic Solutions International Files To Initiate Phase Iii Clinical Trial For Acute Respiratory Distress Syndrome (ARDS) Leveraging Positive Covid-19 Data With Jadicell Stem Cell Therapy
20/04/2023 14:04
April 20 (Reuters) - Therapeutic Solutions International
Inc TSOI.PK :
* THERAPEUTIC SOLUTIONS INTERNATIONAL FILES TO INITIATE
PHASE III
CLINICAL TRIAL FOR ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS)
LEVERAGING POSITIVE COVID-19 DATA WITH JADICELL STEM CELL
THERAPY
Source text for Eikon: ID:nBw7BcfyXa
Further company coverage: TSOI.PK
Recent news on Therapeutic Solutions International
See all newsBrief: Therapeutic Solutions International Files For Orphan Drug Designation Use Of Jadicell Adult Stem Cells
Brief: Therapeutic Solutions International Files To Initiate Phase Iii Clinical Trial For Acute Respiratory Distress Syndrome (ARDS) Leveraging Positive Covid-19 Data With Jadicell Stem Cell Therapy
Brief: Therapeutic Solutions International Files With FDA To Expand Ongoing Phase III Clinical Trial To Include All Causes Of Acute Respiratory Distress Syndrome
Brief: Therapeutic Solutions Granted Emergency IND By FDA For Stem Cell Therapy
Brief: Therapeutic Solutions International Completes Purchase Of FDA Phase Iii Jadicell Stem Cell Investigational New Drug Application From University Of Miami